A realist evaluation of patients’ decisions to deprescribe in the EMPOWER trial

Philippe Martin,¹² Cara Tannenbaum²³

ABSTRACT

Background and objectives Successful mechanisms for engaging patients in the deprescribing process remain unknown but may include: (1) triggering motivation to deprescribe by increasing patients’ knowledge and concern about medications; (2) building capacity to taper by augmenting self-efficacy and (3) creating opportunities to discuss and receive support for deprescribing from a healthcare provider. We tested these mechanisms during the Eliminating Medications through Patient Ownership of End Results (EMPOWER) trial and investigated the contexts that led to positive and negative deprescribing outcomes.

Design A realist evaluation using a sequential mixed methods approach, conducted alongside the EMPOWER randomised clinical trial.

Setting Community, Quebec, Canada.

Participants 261 older chronic benzodiazepine consumers, who received the EMPOWER intervention and had complete 6-month follow-up data.

Intervention Mailed deprescribing brochure on benzodiazepines.

Measurements Motivation (intent to discuss deprescribing; change in knowledge test score; change in beliefs about the risk–benefits of benzodiazepines, measured with the Beliefs about Medicines Questionnaire), capacity (self-efficacy for tapering) and opportunity (support from a physician or pharmacist).

Results The intervention triggered the motivation to deprescribe among 167 (n=64%) participants (mean age 74.6 years±6.3, 72% women), demonstrated by improved knowledge (risk difference, 58.50% (95% CI 57.36% to 74.91%)). Those who attempted to taper exhibited increased self-efficacy (risk difference, 56.90% (95% CI 45.41% to 65.77%)). Contexts where deprescribing mechanisms failed included lack of support from a healthcare provider, a focus on short-term quality of life, intolerance to withdrawal symptoms and perceived poor health.

Conclusion Deprescribing mechanisms that target patient motivation and capacity to deprescribe yield successful outcomes in contexts where healthcare providers are supportive, and patients do not have internal competing desires to remain on drug therapy.

Trial registration number ClinicalTrials.gov: NCT01148186.

INTRODUCTION

Deprescribing refers to the collaborative process of tapering, discontinuing, stopping or withdrawing medications in order to reduce adverse drug events and improve outcomes.¹³ Deprescribing has many steps,¹³ with one key component being the engagement of patients in shared decision-making.¹⁷–¹⁵ Research suggests that older adults have conflicted feelings about medications:⁴ ¹⁴: 78% of older adults believe that medications are necessary to improve health, but at the same time, 68% would like to reduce their current medication use, with 92% willing to stop a regular medication if advised to do so by their physician.¹⁴ A better understanding of the mechanisms that trigger patient motivation and capacity to engage in the deprescribing process could reduce the use of potentially inappropriate medications.

The aim of realist evaluation is to reveal how an intervention might generate different outcomes in different circumstances, and how mechanisms work in particular contexts, by enabling or motivating participants to make different choices.¹⁶ Educational strategies to increase patients’ knowledge, beliefs and motivation are hypothesised to influence deliberate action on the part of the patient to curtail the use of a drug.¹⁶ However, what works, for whom, under which circumstances and why are questions that have never been explored systematically from the patient’s...
point of view. Recent reviews on deprescribing call for a realist evaluation of large deprescribing trials to investigate how the mechanisms underlying deprescribing interventions interact with specific contexts to yield positive or negative outcomes.17,18 The Eliminating Medications through Patient Ownership of End Results (EMPOWER) trial, which demonstrated a number-needed-to-treat of 4 for the effectiveness of mailing a benzodiazepine deprescribing brochure on complete cessation of benzodiazepines at 6 months, provides a timely opportunity to examine which deprescribing mechanisms worked under which circumstances.12

The initial theory underpinning the development of the EMPOWER intervention was that most, if not all, older adults are unaware of the age-related harms of taking benzodiazepine anti-anxiety drugs and sleeping pills. Side effects of sedative-hypnotics are well documented in the literature but rarely talked about in practice as being a potential cause of memory impairment, falls and fractures.19–24 Fear of increased mortality and potential for falls are among the most common patient barriers to deprescribing.18,25,26 Not understanding why medications should be discontinued is a patient barrier to deprescribing.27 As most patients are uninformed of the potential risks associated with the use of benzodiazepines, we hypothesised a linear behaviour change process whereby providing patients with an interactive educational brochure detailing associated risks, safer alternatives and steps for tapering would trigger patients’ motivation, capacity and opportunity to initiate the deprescribing process through discussion of medication discontinuation with a healthcare provider.

This paper reports a realist evaluation of the deprescribing process from the patient’s perspective. The realist evaluation tests the following mechanisms: (1) whether the EMPOWER intervention triggered patients’ motivation to deprescribe by increasing knowledge and concern about benzodiazepines; (2) augmented patients’ capacity and self-efficacy to taper benzodiazepines and (3) created opportunities for the patient to discuss and receive support from a healthcare provider to engage in the deprescribing process. We also determined in which contexts successful and failed deprescribing outcomes occurred.

**METHODS**

**Study design**

A realist evaluation was conducted alongside the EMPOWER randomised controlled trial.12 This report follows online supplementary material 2 RAMESES II guidelines for realist evaluation.16 The approach was chosen to inform the implementation of future deprescribing initiatives by examining the possible causes and contextual factors associated with change.28 Realist evaluation is a theory-based, sequential mixed methods approach that seeks to gain a deeper understanding of contexts, mechanisms and outcomes. This is accomplished through the identification and examination of underlying generative mechanisms (M) associated with the intervention or programme, the conditions or contexts (C) under which the mechanisms operate, and the pattern of outcomes (O) produced. These may be expressed as linked Contexts–Mechanisms–Outcomes configurations (or C+M=O).28 In this case, the (C) consist of all internal and external factors that can influence the deprescribing process and the (O) refer to whether or not the deprescribing intervention was successful. The (M) that we aimed to test were whether the EMPOWER brochure: (1) triggered older adults’ motivation to deprescribe by increasing knowledge and concern about benzodiazepines; (2) built capacity to taper by augmenting self-efficacy and (3) drove opportunities to receive support from a healthcare provider to deprescribe.

The study was approved by the Institut Universitaire de Gériatrie de Montréal Ethics Committee in Montreal, Quebec, Canada.

**Environment surrounding the evaluation**

The EMPOWER trial was a pragmatic randomised trial that examined the effectiveness of a direct-to-consumer, written educational brochure mailed directly to patients on subsequent discontinuation of sedative-hypnotic medication.29 The EMPOWER trial was rolled out between July 2010 and November 2013, with community-dwelling participants randomly recruited via pharmacists located within a 200 km radius of the Montreal urban area in Quebec, Canada. Participants were 303 older, community-dwelling, chronic users of benzodiazepine medication and agreed to home visits and telephone follow-up interviews by the research team. All benzodiazepine prescriptions for seniors were covered under the publicly financed drug plan in the province of Quebec, excluding the programme’s deductible (if applicable). Provincial governments covered physician reimbursements for patient visits, and drug dispensing fees for pharmacists, as part of Canada’s universal healthcare programme.

**The EMPOWER intervention**

The eight-page EMPOWER brochure, available at http://www.criugm.qc.ca/fichier/pdf/BENZOeng.pdf,30 aims to promote active learning by incorporating and using constructivist learning principles.31 The brochure includes a self-assessment component and presentation of the evidence-based risks associated with benzodiazepine use in an effort to elicit cognitive dissonance.32 Elements of social comparison theory,32 through the use of peer champion stories, are also integrated in the intervention. The brochure provides a self-guided tapering schedule, consisting of a visual tapering protocol showing pictures of full pills, halved pills and quartered pills.30

**Evaluation of mechanisms and contexts**

The mechanisms embedded in the EMPOWER intervention are based on Michie et al’s behaviour change wheel,33 targeting motivation, capacity and opportunity. Michie et al define motivation as the mental process that energises
and directs behaviours. Capability refers to the psychological and physical capacity of the individual to engage in the behaviour. Opportunity refers to the internal and external factors that permit or promote a behaviour to happen, and include both the physical and social environment of the individual. Table 1 links the programme mechanisms to the corresponding intervention components.

The evaluation of mechanisms and contexts consisted of quantitative data collection and analysis, qualitative data collection and analysis and triangulation of the quantitative and qualitative results. Data collection was conducted between July 2010 and November 2013 as part of the EMPOWER clinical trial. Analysis, triangulation and refinement of the Context-Mechanism-Outcome configuration took place subsequent to completion of the trial.

**Data collection methods**

Quantitative data included preintervention and 1-week postintervention information on knowledge about benzodiazepine-related harms, beliefs about the necessity of taking benzodiazepines versus concern about harms, self-efficacy for tapering and intent to discuss deprescribing with a healthcare provider. We measured gains in knowledge with the four true or false questions listed in the ‘Test Your Knowledge’ section of the questionnaire. Correct answers were summed to a maximum of 4 points, and answers were compared prior to and after receiving the intervention. Participants’ beliefs about consuming benzodiazepines were measured with the Beliefs about Medicines Questionnaire (BMQ-Specific) at both time points. The BMQ-Specific consists of two validated five-item subscales assessing the respondents’ perceptions about the necessity and concerns associated with taking benzodiazepines. Participants indicate their degree of agreement with each statement on a five-point Likert scale (1=strongly disagree, 5=strongly agree). Scores are summed into their respective subcategory (5–25 point scale) with higher scores indicating stronger beliefs. Risk perception was assessed using a single question 1-week postintervention in which participants were asked whether they perceived the same, increased or no risk from consumption of their benzodiazepine following the intervention. In order to determine whether the EMPOWER brochure increased capacity to taper by augmenting self-efficacy, we measured self-efficacy for tapering on the Medication Reduction Self-efficacy scale, which allows the respondent to rate on a scale of 0 to 100 their degree of confidence for tapering benzodiazepines. Higher scores indicate greater self-efficacy. Participants were also asked to indicate (yes/no) postintervention if they had spoken to or intended to discuss medication discontinuation with their doctor and/or pharmacist. Health status was assessed at baseline using the first item of the Short-Form-12 Health Survey and dichotomised by categorising poor to fair responses as poor health.

Qualitative data were collected after the 6-month follow-up, using semistructured interviews conducted at participants’ homes to determine the contexts under which the deprescribing mechanisms succeeded or failed. Twenty-one participants were strategically sampled for the interviews using a contrast sample design, based on cessation of benzodiazepines (yes or no) combined with intent to discuss tapering (yes or no). Interviews lasted approximately 1 hour, were recorded with consent and professionally transcribed verbatim. The interviews were based on a pre-established discussion guide, the major themes of which included initial reactions to the intervention, reasons underlying the decision to taper, experience with the tapering process and personal interactions with healthcare providers (see online supplementary material 1).

**Analysis**

The three mechanisms of increasing motivation, capacity and opportunity were tested using quantitative analysis.

---

<table>
<thead>
<tr>
<th>Table 1 Programme mechanisms embedded in EMPOWER intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanisms</strong></td>
</tr>
<tr>
<td>Increase motivation to deprescribe by changing knowledge and beliefs</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Increase capacity to taper by augmenting self-efficacy</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Drive opportunities to discuss and initiate deprescribing with a healthcare provider</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Participants with complete follow-up data were included in the quantitative analysis (n=261, mean age 74.6±6.3, 72% women). Data were described and compared using means with SD and independent t-tests for continuous data, and percentages and χ² tests for categorical data, according to each of three outcomes: intent to deprescribe with successful discontinuation, intent to deprescribe with failed discontinuation and no intent to deprescribe. Individuals who achieved a dose reduction were classified as intent to deprescribe with failed discontinuation. Participant changes in knowledge, in the BMQ necessity and concerns subscales and in self-efficacy scores for tapering were computed from baseline to postintervention. Risk differences with 95% CIs were calculated for the proportion of participants in each group who demonstrated increased knowledge, heightened concern about benzodiazepine use and augmented self-efficacy for tapering. The statistical significance for all analyses was set at p<0.05 (two-sided). SPSS V.21.0 was used for all analyses.

Qualitative data from the semistructured interviews were analysed using thematic content analysis to explore the contexts under which the programme mechanisms led to positive or negative outcomes. Discourses were contrasted according to whether participants discontinued benzodiazepines and/or expressed the intent to discuss discontinuation. Interviews were coded using Dedoose software. Contextual themes were derived from the data and supported by quotes. Initially, two researchers independently read the transcripts and field notes, then collaboratively developed first order codes, which were subsequently verified by double coding. Second order thematic coding was performed for the purpose of building concepts.

Quantitative and qualitative results about context were combined and analysed in an iterative fashion through use of a triangulation protocol using a convergence coding matrix, as described by Farmer et al. The convergence matrix served to inform which contexts favourably or unfavourably influenced a patient’s decision to deprescribe based on agreement, partial agreement or dissonance between the quantitative and qualitative data. Differences were adjudicated via discussion and consensus. The convergence-coding matrix is available from the authors on request.

RESULTS

Linking mechanisms to outcomes

The mechanism of triggering motivation to deprescribe occurred in 167 of 261 individuals (64%) who received the EMPOWER intervention (table 2). Participants who expressed an intent to deprescribe postintervention had improved knowledge (risk difference, 58.50% (95% CI 45.41% to 65.77%)) and higher perceived necessity scores (risk difference, 56.03% (95% CI 44.63% to 64.81%)) compared with those in whom the intervention did not trigger motivation (risk difference, 35.14% (95% CI 23.06% to 45.39%)). Individuals who decided to deprescribe exhibited higher capacity for tapering after receipt of the EMPOWER brochure, with enhanced self-efficacy compared with those in whom the intervention did not trigger motivation (risk difference, 56.90% (95% CI 45.41% to 65.77%)) (table 2). Approximately half of individuals with augmented motivation and capacity to deprescribe initiated a conversation with their physician, and 25% spoke to a pharmacist about deprescribing. Neither postintervention self-efficacy scores nor creating the opportunity to discuss deprescribing with a healthcare provider distinguished between positive or negative outcomes among motivated individuals.

Contexts associated with positive deprescribing outcomes

Table 3 shows the results of the qualitative analysis, describing the contexts that enabled the EMPOWER mechanisms to achieve positive deprescribing outcomes. Favourable personal contexts included stable health status and a positive outlook on ageing. Individuals who were not dealing with acute health issues were more receptive to tapering off benzodiazepines, as were individuals who prioritised long life expectancy over the short-term benefits of continued use or the transient discomfort associated with deprescribing benzodiazepines. Individuals who succeeded in tapering had the highest baseline self-efficacy for being able to discontinue (table 2). External influences associated with successful discontinuation were previous and ongoing support or encouragement from a healthcare provider (table 3).

Contexts in which the EMPOWER mechanisms failed

Thirty-six per cent of the participants in the trial reported no desire to deprescribe after receipt of the EMPOWER brochure. These individuals showed no gain in knowledge and no increase in perceived risk post-intervention (table 2). Failure for the EMPOWER intervention to elicit motivation to deprescribe was more likely among individuals who reported poor health (40% vs 28%, 12.28% (95% CI 0.44% to 24.18%)). During the qualitative interviews, participants dealing with ongoing health issues expressed a strong reliance on benzodiazepines for everyday coping (table 4). Other contexts associated with the decision not to attempt deprescribing included previous reassurance by a physician that benzodiazepines were safe or necessary and the belief that the benefits of benzodiazepines outweighed the risks for immediate symptom relief (table 4). Contexts that led participants to abort the deprescribing process once they showed initial motivation, capacity and opportunity to deprescribe included the lack of support from a healthcare provider, intolerance to withdrawal symptoms and a sudden loss of confidence to live without sleeping pills (table 4).
Table 2  Linking mechanisms to outcomes

<table>
<thead>
<tr>
<th>Mechanisms</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All (n=261)</td>
</tr>
<tr>
<td>Increased motivation</td>
<td></td>
</tr>
<tr>
<td>Change in knowledge:</td>
<td></td>
</tr>
<tr>
<td>Baseline knowledge (/4), mean (SD)</td>
<td>0.85 (0.99)</td>
</tr>
<tr>
<td>Postintervention knowledge (/4), mean (SD)</td>
<td>1.92 (1.40)</td>
</tr>
<tr>
<td>Increase in knowledge postintervention, n (%)</td>
<td>156 (59.8)</td>
</tr>
<tr>
<td>Beliefs about benzodiazepines</td>
<td></td>
</tr>
<tr>
<td>Baseline belief about necessity† (/25), mean score (SD)</td>
<td>13.8 (3.4)</td>
</tr>
<tr>
<td>Postintervention belief about necessity†, mean score (SD)</td>
<td>12.58 (3.32)</td>
</tr>
<tr>
<td>Participants with a decrease in score about necessity postintervention, n (%)</td>
<td>138 (52.8)</td>
</tr>
<tr>
<td>Baseline concern†, (/25), mean score (SD)</td>
<td>13.4 (2.7)</td>
</tr>
<tr>
<td>Postintervention concern†, mean score (SD)</td>
<td>14.42 (3.41)</td>
</tr>
<tr>
<td>Participants with increased concern postintervention, n (%)</td>
<td>138 (52.8)</td>
</tr>
<tr>
<td>Risk perception:</td>
<td></td>
</tr>
<tr>
<td>Participants perceiving increased risk postintervention, n (%)</td>
<td>118 (44.8)</td>
</tr>
<tr>
<td>Building capacity</td>
<td></td>
</tr>
<tr>
<td>Self-efficacy for tapering</td>
<td></td>
</tr>
<tr>
<td>Baseline self-efficacy (/100), mean (SD)</td>
<td>37.8 (35.7)</td>
</tr>
<tr>
<td>Postintervention increase in self-efficacy score, mean change (SD)</td>
<td>25.44 (42.78)</td>
</tr>
<tr>
<td>Participants with increased self-efficacy postintervention, n (%)</td>
<td>145 (55.5)</td>
</tr>
<tr>
<td>Creating opportunity</td>
<td></td>
</tr>
<tr>
<td>Outreach to a healthcare professional:</td>
<td></td>
</tr>
<tr>
<td>Discussed with physician, n (%)</td>
<td>103 (39.5)</td>
</tr>
<tr>
<td>Discussed with pharmacist, n (%)</td>
<td>56 (20.1)</td>
</tr>
</tbody>
</table>

*Level of significance, p<0.05.
†As some participants selected more than one condition, total does not equal 100%.
Independent sample t-test for continuous variables, χ² for categorical variables.
Refining the context–mechanism–outcome configuration for deprescribing interventions

The initial context–mechanism–outcome configuration that drove the development of the EMPOWER intervention was a simple, linear progression along different stages of readiness to deprescribe, similar to Prochaska & DiClemente’s transtheoretical model of change (figure 1A).43 We believed that the EMPOWER brochure would trigger motivation and capacity to deprescribe, moving patients from precontemplation about deprescribing to action and maintenance, by increasing knowledge about the harms of benzodiazepines, enhancing self-efficacy and creating opportunities to discuss deprescribing with a healthcare professional. We assumed that the healthcare provider would provide a supportive context, encouraging the patient to deprescribe, thereby yielding a positive outcome. This initial configuration oversimplified the stages through which individuals transitioned after receiving the deprescribing intervention. Figure 1B depicts a revised, non-linear context–mechanism–outcome configuration that takes into account the complexity of internal and external contexts on initiating and completing the deprescribing process from the consumer’s perspective. The revised model recognises that new information influences beliefs and actions only if the information generates a desire strong enough not to be overwhelmed by competing motivations arising from other sources. In many instances, the desire for risk reduction, which was the prime motivator behind the development of the EMPOWER intervention, did not supersede concerns about symptom recurrence, or other psychological and health factors, as well as interpersonal relationships with healthcare providers, which played critical contextual roles in the outcome of the intervention.

DISCUSSION

This realist evaluation tested the mechanisms embedded in the EMPOWER intervention and showed that motivation and capacity to deprescribe were triggered in 64% of older chronic benzodiazepines consumers, the majority of whom created an opportunity to discuss
deprescribing with a healthcare provider. These findings support the theory that provision of new knowledge about medication harms can raise concern and augment patients’ self-efficacy to deprescribe. However, the analysis also indicates that human motivation to deprescribe is complex and unstable. A variety of internal and external contexts can interfere with the decision to deprescribe. Internal influences include perceptions about one’s health status, long-term health goals, fear of symptom recurrence and psychological attachment to the drug. The main external influence that blocks consumer-directed deprescribing mechanisms is the lack of support from a healthcare provider.

Our findings contribute to the literature by illustrating that linear progression along different stages of readiness to deprescribe does not fully explain successful deprescribing from the patient’s perspective. This conclusion is consistent with other critiques of the transtheoretical model, which claim that the stages of readiness are arbitrary, that human beings do not make logical and stable plans to change their behaviour and that setbacks can occur along the trajectory of change. Education appears to be necessary but insufficient for many individuals, and new strategies will be needed to trigger deprescribing in prohibitive contexts where the EMPOWER mechanisms failed. As capacity and motivations change over time,

Table 4  Contexts associated with negative outcomes

<table>
<thead>
<tr>
<th>Key theme</th>
<th>Successful deprescribing (n=7)</th>
<th>Failed deprescribing (n=7)</th>
<th>No attempt to deprescribe (n=7)</th>
<th>Supporting citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous discouragement from physician</td>
<td>1 (14%)</td>
<td>1 (14%)</td>
<td>5 (71%)</td>
<td>‘I asked him (my doctor), ‘Are there any of my medications I could stop?’ He told me, ‘No, we’re not taking anything away, you are doing well’. I then told him my medication was getting very expensive to which he replied, ‘You know Mr., life is priceless’. (75-year-old man, no intent to taper)</td>
</tr>
<tr>
<td>Poor health status</td>
<td>0</td>
<td>1 (14%)</td>
<td>4 (57%)</td>
<td>‘If anyone stops my pills, poof, I would die for sure because of my poor health’. (70-year-old woman, no intent to taper)</td>
</tr>
<tr>
<td>Unquestioning belief in their physician</td>
<td>1 (14%)</td>
<td>1 (14%)</td>
<td>3 (43%)</td>
<td>‘If you take all your pills as prescribed, you’ll never have problems in your life […] When my doctor prescribes something for me, I know it’s not junk, I know it’s good for me. And I don’t question it’. (72-year-old man, no intent to taper)</td>
</tr>
<tr>
<td>Lack of perception of personal risk</td>
<td>1 (14%)</td>
<td>2 (29%)</td>
<td>5 (71%)</td>
<td>‘I recall that he (my doctor) told me that in the long-term my benzodiazepine could affect my memory. But my memory is fantastic’. (72-year-old man, no intent to taper)</td>
</tr>
<tr>
<td>Reliance on medication for coping/everyday function</td>
<td>1 (14%)</td>
<td>1 (14%)</td>
<td>4 (57%)</td>
<td>‘Without this medication, I know that my life would be plagued by anxiety, of this I am certain’. (68-year-old woman, no intent to taper)</td>
</tr>
<tr>
<td>Quality of life focus during end of life</td>
<td>0</td>
<td>2 (29%)</td>
<td>3 (43%)</td>
<td>‘At my age I don’t care about the risks. I don’t care if I live to 100 or not’. (85-year-old woman, failed tapering)</td>
</tr>
<tr>
<td>Discouragement from a physician</td>
<td>1 (14%)</td>
<td>3 (43%)</td>
<td>5 (71%)</td>
<td>‘My doctor told me: ‘At your age, don’t worry about it. You’ve been taking this pill for a while and you are fine. You aren’t taking a dangerous dose at all’. (85-year-old woman, failed tapering)</td>
</tr>
<tr>
<td>Intolerance to recurrence of symptoms/withdrawal effects</td>
<td>0</td>
<td>5 (71%)</td>
<td>–</td>
<td>‘When I decreased the dose I started getting headaches. I felt miserable not being able to sleep at night’. (85-year-old man, failed tapering)</td>
</tr>
<tr>
<td>Loss of confidence to complete the tapering process (postintervention)</td>
<td>0</td>
<td>4 (57%)</td>
<td>4 (57%)</td>
<td>‘I knew that I’d be in trouble without my pills. It’s been a long time now. How can I put it in words? If I ran out of pills I’d be in trouble’. (85-year-old man, failed tapering)</td>
</tr>
</tbody>
</table>
Figure 1  (A) Initial deprescribing context–mechanism–outcome configuration. (B) Refined deprescribing context–mechanism–outcome configuration.
reminders and ongoing discussions about the risks of inappropriate medications may progressively trigger and sustain patients’ commitments to engage in the deprescribing process. Some competing factors may wane, such as poor health. Offering cognitive behavioural therapy to patients during the most difficult last quarter period of the tapering protocol may augments self-efficacy for overcoming withdrawal symptoms. Interventions can be directed at healthcare providers who discourage deprescribing efforts. Continuing medical education to inform health providers about the mounting evidence on the harms of benzodiazepine use may curtail the phenomenon of physicians who continue to promote the use of inappropriate medication. Future research directions should also include measurement of cognitive dissonance, which lies at the heart of constructivist learning. Methods to measure cognitive dissonance, defined as a feeling of tension between two sets of competing beliefs and motivations, may shed light on the way in which tensions about deprescribing are played out and drive behaviour change. As we did not directly ask patients if they felt internal tension, we were unable to record feelings or processes of cognitive dissonance. Use of a mixed methods approach enabled us to explore the breadth, depth and complexity of the patient’s experience of deprescribing from a social, behavioural and health perspective, allowing stronger inferences about the various contexts affecting patients’ decisions than could be achieved through a quantitative or qualitative lens alone. However, other mechanisms and contexts may trigger motivation to deprescribe beyond what is described in this realist evaluation. One untested mechanism is provision of information about the lack of drug benefits in certain populations, such as statins to reduce cholesterol levels in palliative care patients with limited life expectancy. Another challenge that we experienced during the conduct of this realist evaluation was differentiating between the mechanisms and contexts associated with deprescribing. For instance, when participants stated that their physician or pharmacist undermined their decision to deprescribe, it was clear this factor changed the reasoning of the participants. However, we were not sure whether this factor should be labelled as a mechanism or a context. Since the mechanism of action is defined as the ‘how’ behind the generation of outcomes, we initially thought that healthcare provider support was a mechanism that brought about deprescribing. On iterative reflection and discussion of the C–M–O configurations, we came to the conclusion that healthcare provider support was actually a context that enabled or hindered the consumer’s motivation, capacity and opportunity to deprescribe, as triggered by the EMPOWER intervention. We drew this conclusion by subscribing to Pawson and Tilley’s initial approach to realist evaluation, which seeks to identify mechanisms at the level of the individual’s human reasoning. Others such as Dalkin et al posit that interpersonal relationships between stakeholders are a key factor that influence human reasoning, and argue that mechanisms can also be evaluated through the social lens of human and systems interactions. Deprescribing in particular is a complex social process that involves patients, prescribers and pharmacists, so our analysis may be faulted by some for studying the consumer’s decision-making processes in isolation. For this reason, we chose not to make a table listing discrete C–M–O relationships in this paper but instead focused on broadly describing and testing the mechanisms embedded in the EMPOWER intervention and outlining the different personal, interpersonal and external contexts that led to positive or negative outcomes. We created figure 1A,B with difficulty, and some scepticism about whether these complex interactions could be illustrated in simple form. As the field of realist evaluation evolves, new terminology and formats may emerge that better capture a way of graphically illustrating the science of human interactions and behaviour change.

In conclusion, this realist evaluation conducted alongside a clinical trial provides important insights about deprescribing from the patient’s perspective and increases current understanding about the specific mechanisms and contexts that generate positive or negative outcomes when attempting to engage patients in curbing the overuse and potentially inappropriate use of medicines.

Acknowledgements We wish to acknowledge the work of Anne-Sophie Michaud and Anastasios Soboleva who conducted the in-home interviews and helped in identifying first order coding for the qualitative portion of the manuscript. Additionally, we would like to thank Johanne Collin for her advice in devising the general strategy for the qualitative interviews. We express gratitude to all the participants and pharmacists who took part in this trial. Particular thanks are offered to the Pharmacy Services Department of the Jean Coutu Group (JUC) Inc. for their collaboration and support.

Contributors PM and CT contributed to the study concept and design, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content and final approval of the version to be published.

Funding This work was supported by Operating Grant OTG-88591 from the Canadian Institutes of Health Research (CIHR). PM received a doctoral bursary from the FRSQ. CT was supported by a Senior Scientist Career Award from the FRSQ. The above funding organisations had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.

Competing interests None declared.

Ethics approval Institut Universitaire de Gériatrie de Montréal Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Dataset is available upon request to the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


38. sunny C, McDonald DW, Landay JA. Theory-driven design strategies for technologies that support behavior change in everyday life. New York NY: ACM.
40. Hilmer SN, Gnjidic D, Le Couteur DG. Thinking through the medication list - appropriate prescribing and deprescribing in robust and frail older patients. Aust Fam Physician 2012;41:924.
A realist evaluation of patients' decisions to deprescribe in the EMPOWER trial

Philippe Martin and Cara Tannenbaum

BMJ Open 2017 7:
doi: 10.1136/bmjopen-2017-015959

Updated information and services can be found at:
http://bmjopen.bmj.com/content/7/4/e015959

These include:

References
This article cites 42 articles, 8 of which you can access for free at:
http://bmjopen.bmj.com/content/7/4/e015959#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Geriatric medicine (287)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/